Chimeric antigen receptors (CARs) are artificial immunoreceptors that drive T cell-mediated tumor destruction. CAR-modified T cells have demonstrated unprecedented clinical success, leading to six FDA ...

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results Twenty-eight ...

Chimeric antigen receptor (CAR) T-cell therapy represents a paradigm shift in the treatment of relapsed or refractory haematological cancers by harnessing patients’ own immune cells to target surface ...

Physician-researchers with City of Hope have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor (CAR) T cell therapy resistance. Their new system ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now discovered that CAR molecules can be transferred from the CAR-T cells to ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), ...

A pioneering Phase I CAR T cell therapy trial for the treatment of glioblastoma at City of Hope demonstrates promising clinical activity against incurable brain tumors, according to research published ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...